Repatha (Evolocumab)
Indications
The U.S. FDA expanded the evolocumab label in August 2025 to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled LDL-C — removing the prior requirement for a documented cardiovascular disease diagnosis. The HoFH indication was simultaneously expanded to permit monotherapy use. The full set of FDA-approved indications is shown below.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| MACE risk reduction — reducing risk of CV death, MI, stroke, unstable angina requiring hospitalisation, or coronary revascularisation | Adults at increased risk for these events (with or without prior diagnosed CV disease) | Used in conjunction with diet and exercise | FDA Approved |
| Primary hyperlipidaemia (including heterozygous familial hypercholesterolaemia [HeFH]) — to reduce LDL-C | Adults with hypercholesterolaemia; paediatric patients ≥10 years with HeFH | Adjunct to diet and exercise, with or without other LDL-C–lowering therapies | FDA Approved |
| Homozygous familial hypercholesterolaemia (HoFH) — to reduce LDL-C | Adults and paediatric patients ≥10 years | Monotherapy or adjunct to diet and other LDL-C–lowering therapies (e.g., statins, ezetimibe, LDL apheresis) | FDA Approved |
The MACE-reduction indication is supported by two large outcome trials. FOURIER (2017) demonstrated a 15% reduction in the primary composite endpoint among 27,564 adults with established ASCVD on statin therapy. VESALIUS-CV (NEJM, November 2025) extended that benefit to a primary prevention–like population: 12,257 adults with atherosclerosis or diabetes but no prior MI or stroke achieved a 25% relative reduction in coronary heart disease death, MI, or ischaemic stroke over a median 4.6 years of follow-up.
Statin intolerance with high cardiovascular risk — supported by GAUSS-3 in patients with confirmed statin-associated muscle symptoms. The 2025 label expansion now covers most of these patients within the MACE-risk indication, narrowing the truly off-label space. Evidence quality: moderate.
Lipoprotein(a) reduction as a primary therapeutic target — evolocumab lowers Lp(a) by ~25–30%; whether this contributes independently to outcome benefit is unproven. Evidence quality: low.
Acute coronary syndrome, in-hospital initiation — small trials (EVOPACS, EVACS) show rapid LDL-C reduction; broader adoption awaits outcome data dedicated to this setting. Evidence quality: low to moderate.
Paediatric use under age 10 — safety and efficacy not established. Evidence quality: insufficient.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| MACE risk reduction in adults at increased risk (with or without prior CVD) | 140 mg SC every 2 weeks or 420 mg SC monthly | Same as starting dose | 420 mg per month (regimens are not additive) | Both regimens produce equivalent steady-state LDL-C reduction When switching regimens, give the first dose of the new regimen on the next scheduled date of the prior regimen |
| Primary hyperlipidaemia / HeFH — adults | 140 mg SC every 2 weeks or 420 mg SC monthly | Same as starting dose | 420 mg per month | LDL-lowering effects measurable as early as 4 weeks after initiation For monthly dosing, measure LDL-C just before next scheduled dose to capture trough |
| HeFH — paediatric ≥10 years | 140 mg SC every 2 weeks or 420 mg SC monthly | Same as starting dose | 420 mg per month | HAUSER-RCT studied monthly dosing only; both regimens are FDA-approved for this population Adult-equivalent dosing — no weight-based scaling required |
| HoFH — adults and paediatric ≥10 years | 420 mg SC monthly | 420 mg SC monthly | 420 mg SC every 2 weeks | If clinically meaningful response not achieved at 12 weeks, may up-titrate to 420 mg every 2 weeks Measure LDL-C 4–8 weeks after initiation; response depends on residual LDL-receptor function |
| Patients on lipid apheresis | 420 mg SC every 2 weeks (to align with apheresis schedule) | Continue post-apheresis dosing | — | Administer evolocumab after each apheresis session Apheresis acutely removes circulating IgG; post-session timing preserves trough levels |
| Administering the 420 mg dose | Three consecutive 140 mg SureClick autoinjector injections within 30 minutes | The Pushtronex on-body infusor was discontinued 30 June 2024 Use different injection sites for the three consecutive injections | ||
| Missed dose | Administer as soon as remembered if more than 7 days remain until the next scheduled dose; otherwise skip and resume the original schedule | Do not double-dose to compensate | ||
Population-Specific Considerations
| Population | Adjustment | Rationale |
|---|---|---|
| Renal impairment (any eGFR, including ESRD/dialysis) | No adjustment | Cleared by reticuloendothelial protein catabolism; not renally excreted |
| Hepatic impairment — Child-Pugh A or B | No adjustment | Hepatic metabolism not relevant for IgG antibodies |
| Hepatic impairment — Child-Pugh C (severe) | No data available | Pharmacokinetics not characterised in this group; use with caution |
| Elderly (≥65 years) | No adjustment | Approximately 41% of FOURIER participants were ≥65 years with no overall difference in safety or efficacy |
| Paediatric <10 years | Not recommended | Safety and efficacy not established |
| Pregnancy | Discontinue unless benefit clearly outweighs risk | IgG crosses placenta in increasing amounts during 2nd–3rd trimester; long-term LDL lowering is rarely time-critical during gestation |
The two regimens are pharmacodynamically equivalent at steady state; the choice should be driven by patient preference for injection frequency and tolerance for receiving three consecutive injections. The 420 mg monthly regimen requires three 140 mg SureClick injections within 30 minutes. The Pushtronex on-body infusor that previously delivered 420 mg in a single application was discontinued by Amgen on 30 June 2024 and is no longer available; the prefilled syringe was discontinued in early 2026, leaving the SureClick autoinjector as the sole device.
Pharmacology
Mechanism of Action
Evolocumab is a fully human IgG2 monoclonal antibody that binds with high affinity to circulating proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally binds the hepatic LDL receptor and accelerates its lysosomal degradation following receptor-mediated endocytosis. By neutralising free PCSK9 in plasma, evolocumab prevents this degradation cycle, allowing more LDL receptors to recycle to the hepatocyte surface. The resulting upregulation of functional LDL receptors increases hepatic clearance of LDL-cholesterol from the bloodstream.
Clinically, this typically translates to LDL-C reductions on the order of 55–60% on top of statin therapy, with onset of effect within 1–2 weeks. In FOURIER, evolocumab lowered median LDL-C from a baseline of 92 mg/dL to 30 mg/dL; in VESALIUS-CV, achieved on-treatment LDL-C was approximately 40–45 mg/dL. Modest reductions in apolipoprotein B, non-HDL cholesterol, triglycerides, and lipoprotein(a) (~25–30%) are also observed, with a small rise in HDL-C.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Estimated SC bioavailability ~72%; Tmax 3–4 days; mean trough concentrations of ~22–26 mcg/mL with 420 mg monthly | Onset of LDL-C lowering within 1–2 weeks; non-linear kinetics due to target binding |
| Distribution | Apparent volume of distribution ~3.3 L (largely intravascular) | Limited tissue penetration — effects are restricted to extracellular PCSK9 in plasma |
| Metabolism | Non-saturable proteolytic catabolism (reticuloendothelial system) plus saturable target-mediated clearance via PCSK9 binding | No CYP involvement — drug-drug interactions via metabolic enzymes are not expected |
| Elimination | Effective half-life of approximately 11–17 days; not renally or hepatically excreted as a small molecule | Half-life supports q2wk or monthly dosing; no dose adjustment for renal or mild–moderate hepatic impairment |
Statins increase circulating PCSK9, which can shorten the apparent half-life of evolocumab through enhanced target-mediated clearance. This does not undermine clinical effect — patients on statins still achieve substantial additional LDL-C reduction with evolocumab and reach lower absolute LDL-C levels than either drug alone. The interaction is desirable and does not require dose modification.
Side Effects
Evolocumab is among the better-tolerated lipid-lowering agents. Adverse-event rates closely mirror placebo across most categories, with absolute differences typically below one percentage point. The figures below are drawn from the FOURIER cardiovascular outcomes trial (n=27,564) and from the pooled placebo-controlled hyperlipidaemia trials (8 trials, n=2,651 evolocumab-exposed) cited in the FDA prescribing information.
| Adverse Effect | Incidence (Evolocumab vs Placebo) | Clinical Note |
|---|---|---|
| Diabetes mellitus | 8.8% vs 8.2% | Small absolute excess; no mechanism-based concern given that genetic PCSK9 loss-of-function carriers show similar trends. Monitor glycaemic status per usual cardiovascular care. |
| Nasopharyngitis | 7.8% vs 7.4% | Self-limited; not a reason to discontinue. |
| Upper respiratory tract infection | 5.1% vs 4.8% | Mechanism unclear; no signal of opportunistic infection. |
| Adverse Effect | Note on Frequency | Clinical Note |
|---|---|---|
| Nasopharyngitis | Common (>5%) | Reported across the pooled hyperlipidaemia trials at rates greater than placebo. |
| Upper respiratory tract infection | Common (>5%) | Generally mild and self-limited. |
| Influenza | Common (>5%) | Distinguish from injection-site reaction by absence of local findings. |
| Back pain | Common (>5%) | Mechanistic link to drug not established; comparable to background rates. |
| Local injection-site reaction (erythema, pain, bruising) | 3.2% vs 3.0% (pooled trials); 2.1% vs 1.6% (FOURIER) | Most common in the first 1–2 doses. Rotate sites and bring autoinjector to room temperature before injection. |
| Hypersensitivity reactions (predominantly rash) | 5.1% vs 4.7% (pooled); rash 1.0% vs 0.5% | Most reactions are mild rash, eczema, erythema, or urticaria. Severe hypersensitivity reactions mandate discontinuation. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypersensitivity reaction (incl. angioedema) | Rare (post-marketing reports) | Hours to days post-dose | Permanent discontinuation; treat per standard of care; monitor until resolved |
| Anti-drug binding antibody formation | Detected in a small number of patients in clinical trials; not detected in paediatric patients | Variable; first months of therapy | No impact on PK, efficacy, or safety has been demonstrated; routine testing not recommended |
| Neutralising antibodies | Not detected in clinical trials to date | — | No standard testing recommended |
| Neurocognitive adverse events | No excess vs placebo demonstrated (EBBINGHAUS) | Variable | No causal relationship demonstrated; routine cognitive monitoring not required |
| Latex hypersensitivity reaction (legacy device formats only) | Rare | Within minutes to hours of injection | Use the latex-free SureClick autoinjector presentation introduced in 2025 |
| Reason for Discontinuation | Relative Frequency | Context |
|---|---|---|
| Injection-site reaction | Most common pharmacology-specific reason | Often resolves with site rotation, bringing the autoinjector to room temperature, and topical care. |
| Hypersensitivity / allergic-type reactions | Less common | Mandates permanent discontinuation if severe (e.g., angioedema, anaphylaxis-type symptoms). |
| Patient preference / inconvenience | Minor contributor | Switching from monthly dosing (3 sequential injections) to q2-weekly dosing (single injection) can rescue adherence in patients with injection burden. |
Most reactions resolve within 24–48 hours. Standard mitigation: bring the autoinjector to room temperature for at least 30 minutes before injection, rotate sites between abdomen, thigh, and upper arm, and avoid injecting into bruised, red, tender, or scarred tissue. Topical hydrocortisone or oral antihistamine helps for persistent erythema. For patients on the 420 mg monthly regimen who tolerate the medication poorly because of three consecutive injections, switching to 140 mg every 2 weeks (a single injection) may improve adherence.
Drug Interactions
Because evolocumab is cleared by general protein catabolism rather than CYP-mediated metabolism, classical drug-drug interactions involving cytochrome enzymes, P-glycoprotein, or hepatic transporters do not apply. The clinically meaningful interactions are pharmacodynamic — predictable lipid-related effects when combined with other LDL-lowering agents — plus practical considerations around lipid apheresis.
Evolocumab has one of the cleanest interaction profiles in cardiology pharmacology. The clinician’s main decisions are which background lipid agents to combine it with and how to time administration around lipid apheresis — not metabolic enzyme conflicts.
Monitoring
-
Lipid Panel (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C)
Baseline, then 4–8 weeks after first dose, then annually
Routine Confirm on-treatment LDL-C reduction. For monthly dosing, schedule the follow-up draw close to the next scheduled dose to capture the trough. The PI states LDL-lowering effects are measurable as early as 4 weeks after initiation. -
Apolipoprotein B
Baseline (optional); repeat with major regimen change
Trigger-based Useful in patients with metabolic syndrome, hypertriglyceridaemia, or discordant LDL-C / non-HDL-C results — apo B better reflects atherogenic particle number in these settings. -
Lipoprotein(a)
Once at baseline (lifetime measurement)
Routine Lp(a) is largely genetically determined and stable across life — a single measurement informs lifetime risk and identifies patients who may benefit most from PCSK9 inhibition. -
Liver Function Tests
Not routinely required
Trigger-based Evolocumab does not cause hepatotoxicity. LFT monitoring is driven by background statin therapy or other agents, not by evolocumab itself. -
Creatine Kinase
Only if muscle symptoms develop
Trigger-based Evolocumab itself does not appear to cause myopathy. CK testing helps distinguish drug-related myalgia from coincidental statin-related symptoms when concomitant statin therapy is used. -
Glycaemic Status (HbA1c, fasting glucose)
Per cardiovascular and diabetes prevention guidelines
Routine FOURIER reported diabetes mellitus in 8.8% of evolocumab-treated patients vs 8.2% on placebo — a small absolute difference. Continue routine cardiovascular surveillance for diabetes; no drug-specific extra monitoring is mandated. -
Blood Pressure
At each visit
Routine Routine cardiovascular monitoring; not specifically driven by evolocumab. -
Injection Site / Tolerability
First 1–3 doses, then PRN
Routine Inspect injection sites for erythema, induration, or signs of hypersensitivity. Most reactions occur early; persistent or worsening reactions warrant attention. -
Anti-Drug Antibodies
Not routinely tested
Trigger-based Anti-drug binding antibodies have been detected in a small number of trial patients without demonstrable impact on PK, efficacy, or safety. Routine ADA testing is not recommended. -
Cognition
Patient-reported at routine visits
Routine EBBINGHAUS, the prospective cognitive substudy of FOURIER, showed no neurocognitive decline with very low achieved LDL-C. Open-ended enquiry about memory and concentration helps address patient concerns.
For routine evolocumab monitoring, two tests dominate: a baseline lipid panel and a follow-up panel 4–8 weeks after the first dose to confirm adequate LDL-C reduction. Once stability is demonstrated, annual lipid testing is sufficient for most patients in the absence of new symptoms or adherence concerns.
Contraindications & Cautions
Absolute Contraindications
- History of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha — including prior angioedema
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment (Child-Pugh C) — pharmacokinetics not characterised; consider lipidology or hepatology input before initiation
- Pregnancy — IgG antibodies cross the placenta in the second and third trimester; long-term LDL lowering is rarely time-critical and therapy is typically discontinued, though continuation may be appropriate in HoFH if benefit clearly outweighs risk
- Active malignancy under treatment — not a true contraindication, but defer initiation until oncology priorities are settled and the patient’s lipid trajectory can be re-evaluated
Use with Caution
- Latex allergy — historically the SureClick autoinjector and prefilled syringe needle covers contained dry natural rubber (a derivative of latex). Latex-free SureClick autoinjectors became available in 2025; verify the device version with the dispensing pharmacy
- History of allergy to monoclonal antibody biologics — observe the first 1–2 doses, ideally in a clinical setting, and counsel on hypersensitivity warning signs
- Lactating patients — limited data; oral bioavailability of IgG in infants is minimal but a risk-benefit discussion is advisable
Evolocumab does not carry an FDA boxed warning. The principal regulatory caution in the prescribing information concerns hypersensitivity reactions, including angioedema, which mandate permanent discontinuation if serious. Counsel patients to recognise warning symptoms — facial, lip, or tongue swelling, generalised urticaria, or breathing difficulty — and to seek emergency care if these develop.
Long-term safety has been characterised through the FOURIER open-label extension (FOURIER-OLE), with maximum exposure of 8.4 years. No new long-term safety signals were identified, including no excess of malignancy, neurocognitive decline, or other unanticipated harms.
Patient Counselling
Purpose of Therapy
Explain that evolocumab is a long-acting injection that lowers “bad” cholesterol (LDL) by helping the liver clear it from the blood more efficiently. It is added to — not a replacement for — a healthy diet, exercise, and any statin or other lipid-lowering medication the patient is already taking. Most patients see a 50–60% drop in LDL-C, which translates to a meaningful reduction in heart attack and stroke risk over the years they remain on therapy. Benefit accrues over time and depends on consistent dosing.
How to Take
Evolocumab is given as a subcutaneous injection in the abdomen, thigh, or upper arm using the SureClick autoinjector. The 140 mg dose is delivered as a single injection every 2 weeks. The 420 mg monthly dose is delivered as three sequential 140 mg SureClick injections within a 30-minute window. Devices should be kept refrigerated and brought to room temperature for at least 30 minutes before injection to reduce stinging. Inject into a different site each time, avoid bruised, hard, red, or tender skin, and never re-use a device. If a dose is missed, take it as soon as possible if more than 7 days remain until the next scheduled dose; otherwise resume the original schedule and do not double-dose.
Sources
- U.S. Food and Drug Administration. Repatha (evolocumab) prescribing information (BLA 125522, 2025 label). Amgen Inc. FDA label PDF (s045) Most current FDA-approved labelling, incorporating the August 2025 expansion of the MACE-risk indication and the HoFH monotherapy indication.
- Amgen press release. Repatha now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C. 25 August 2025. Amgen newsroom Documents the FDA’s broadening of the indication beyond established CVD and the addition of HoFH monotherapy approval.
- European Medicines Agency. Repatha (evolocumab) summary of product characteristics. EMA EPAR European prescribing reference covering EU-specific indications and paediatric population data.
- Amgen. Important notice — Discontinuation of the Repatha Pushtronex System (effective 30 June 2024) and the prefilled syringe (Q1 2026). Repatha HCP — device update Documents the current device landscape: only the SureClick autoinjector remains commercially available, with a latex-free version introduced in 2025.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722. DOI: 10.1056/NEJMoa1615664 Pivotal cardiovascular outcomes trial — 27,564 patients with established ASCVD; basis for the original MACE-risk indication.
- O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation. 2022;146(15):1109-1119. DOI: 10.1161/CIRCULATIONAHA.122.061620 Open-label extension demonstrating durable LDL-C lowering and continued benefit through up to 8.4 years of total exposure.
- Bohula EA, et al. Effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke: primary results of the VESALIUS-CV study. N Engl J Med. 2025; presented at AHA Scientific Sessions, 8 November 2025. Amgen — VESALIUS-CV results Phase 3 trial of 12,257 high-risk adults without prior MI or stroke; 25% relative reduction in CHD death, MI, or ischaemic stroke. Supports the August 2025 FDA primary-prevention–like indication.
- Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance (GAUSS-3). JAMA. 2016;315(15):1580-1590. DOI: 10.1001/jama.2016.3608 Trial supporting use in confirmed statin-intolerant patients via blinded statin/placebo rechallenge.
- Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B). Lancet Diabetes Endocrinol. 2017;5(4):280-290. DOI: 10.1016/S2213-8587(17)30044-X Key efficacy trial in HoFH (including paediatric patients aged 13 years and older), supporting the 420 mg monthly dose and long-term safety in this population.
- Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia (HAUSER-RCT). N Engl J Med. 2020;383(14):1317-1327. DOI: 10.1056/NEJMoa2019910 Phase 3 RCT in adolescents 10–17 years with HeFH; supported the paediatric HeFH indication. Studied 420 mg monthly dosing.
- Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab (EBBINGHAUS). N Engl J Med. 2017;377(7):633-643. DOI: 10.1056/NEJMoa1701131 Prospective neurocognitive substudy of FOURIER demonstrating no decline in cognitive function despite very low achieved LDL-C.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/Multisociety guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. DOI: 10.1016/j.jacc.2018.11.003 Defines the role of PCSK9 inhibitors as second-line non-statin therapy in very high-risk ASCVD patients.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. DOI: 10.1093/eurheartj/ehz455 European guidance with low LDL-C targets in very high-risk patients (<1.4 mmol/L), supporting earlier PCSK9 inhibitor use.
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering. J Am Coll Cardiol. 2022;80(14):1366-1418. DOI: 10.1016/j.jacc.2022.07.006 Practical algorithm for incorporating PCSK9 inhibitors, ezetimibe, bempedoic acid, and inclisiran into clinical practice.
- Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. DOI: 10.1056/NEJMoa054013 Foundational genetic study identifying PCSK9 loss-of-function as cardioprotective — the rationale for therapeutic PCSK9 inhibition.
- Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387-393. DOI: 10.1097/MOL.0000000000000114 Review of the molecular mechanism by which PCSK9 promotes LDL-receptor degradation — context for evolocumab’s pharmacology.
- Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57(7):769-779. DOI: 10.1007/s40262-017-0620-7 Comprehensive review of evolocumab PK/PD including target-mediated disposition and statin co-administration effects.
- Gibbs JP, Doshi S, Kuchimanchi M, et al. Impact of target-mediated elimination on the dose and regimen of evolocumab. J Clin Pharmacol. 2017;57(5):616-626. DOI: 10.1002/jcph.840 Modelling work explaining why 140 mg q2wk and 420 mg monthly produce equivalent steady-state LDL-C reduction.
- Santos RD, Wiegman A, Caprio S, et al. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies (TAUSSIG, RAMAN, HAUSER-OLE). Arterioscler Thromb Vasc Biol. 2024. DOI: 10.1161/ATVBAHA.123.320268 Pooled paediatric HoFH safety and efficacy analysis — basis for the paediatric (≥10 years) HoFH indication.